Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to Deliver Opening Address at the Massachusetts State Science...
April 28 2015 - 9:02AM
Business Wire
Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:
OCAT), a leader in the field of Regenerative Ophthalmology™,
today announced that its chief scientific officer, Robert Lanza,
M.D., will be delivering the opening address to the judges and
students at the Massachusetts State Science & Engineering Fair
(MSSEF) being held at the Massachusetts Institute of Technology, in
Cambridge, MA on May 1st, 2015.
“Dr. Lanza’s pioneering research in cell biology and
regenerative medicine provides hope for millions of people who may
one day benefit from new therapies derived from Bob’s work.
Remarkably, this work was first recognized as part of an academic
science fair” said Dr. Paul Wotton, president and chief executive
officer of Ocata Therapeutics. “Bob is a uniquely talented
individual who is passionate about contributing to the community of
younger scientists, who may in turn generate the breakthrough
inventions of the future”.
The Massachusetts State Science & Engineering Fair, founded
in 1949 by the prestigious American Academy of Arts & Sciences,
has advanced science literacy and inspired new generations of
science of science and engineering leaders for over six decades.
Dr. Lanza will also address the students at the Official Opening of
2015 MSSEF, providing inspiration to four hundred of the most
talented students with the highest quality projects from across the
Commonwealth who will be showcasing their inventions and
discoveries. Over 200 distinguished scientists and engineers from
business, industry and academia will serve as judges, providing the
year-end competition with over $525,000 in scholarships and prizes
for students who excel.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology
company focused on the development and commercialization of
regenerative ophthalmology therapeutics. Ocata’s most advanced
products are in clinical trials for the treatment of Stargardt’s
macular degeneration, dry age-related macular degeneration, and
myopic macular degeneration. Ocata’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and
induced pluripotent stem cell (iPSC) – and other cell therapy
research programs. For more information, visit www.ocata.com.
for Ocata Therapeutics, Inc.Investors:Westwicke
PartnersJohn Woolford,
443-213-0506john.woolford@westwicke.comorPress:Russo PartnersDavid
Schull, 858-717-2310david.schull@russopartnersllc.com
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Apr 2024 to May 2024
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From May 2023 to May 2024